Short answer
Tango Therapeutics, Inc. (TNGX) filed its fiscal 2025 10-K annual report with the SEC on Mar 5, 2026. It reported revenue of $62M (+48.3% year over year) and net income of −$102M.
- Top risk flagged: Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
FY2025 key financial metrics · XBRL
- Revenue
- $62M
- +48.3% YoY
- Net income
- −$102M
- +22.0% YoY
- Operating margin
- -178.4%
- +167.7 pp YoY
- EPS (diluted)
- −$0.87
- +26.9% YoY
- ROE
- -29.3%
- +36.0 pp YoY
- Operating cash flow
- −$139M
- −5.6% YoY
Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) FY2025 10-K on SEC EDGAR. USD.
Tango Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Risk Factors
- Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
- Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises
- Operational vulnerability: Dependence on third-party CROs and manufacturers for preclinical and clinical trial execution and drug supply management
- Competitive risk: Combination therapy trials with Revolution Medicines’ RAS inhibitors and Erasca’s ERAS-0015 molecular glue amid oncology market competition
- Financial risk: Net losses averaging ~$111M in 2025 with accumulated deficit $603.2M, no current product revenue, reliance on equity financing and collaboration revenue
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.